Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO)
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
WHO: The investigators are recruiting children and young adults to participate in a research
study who:
1. Have been diagnosed with Alternating Hemiplegia of Childhood (AHC)
2. Are between the ages of 6 months - 25 years old
3. Have at least three 10-minute-long AHC episodes during a typical week
4. Can commit to 12 weeks of completing of a daily log describing AHC episodes and to a
multi-night hospital stay at the University of Utah Center for Clinical and
Translational Science (CCTS)
WHY: The goal of this study is to evaluate whether the study drug can safely and effectively
decrease AHC episodes and improve the quality of life of individuals with AHC.
WHAT and WHERE: This study involves at least 12 weeks of completing and submitting daily AHC
Episode Logs and a five-day hospital stay at the University of Utah CCTS.
There are 4 phases of the study, and they include:
1. Six weeks of daily log completion prior to starting study drug
2. Five day stay at the University of Utah CCTS
3. Six additional weeks of daily log completion while using study drug at home
4. One day clinic visit to the University of Utah for follow up
COMPENSATION:
There is no fee to participate. All procedures performed specifically for this study will be
covered by the study and will not be billed to you or your insurance company.
The study drug will be dispensed to you free of charge. Meals and lodging at the study site
will be provided free of charge for the study participant and one care provider.
Additionally, the research team will assist subjects with booking and obtaining free
transportation, such as an airline tickets, to and from the study site.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Utah
Collaborators:
Alternating Hemiplegia of Childhood Foundation Jazz Pharmaceuticals